Related Experiment Video
Updated: Jul 18, 2026
08:04
Human Pseudoislet System for Synchronous Assessment of Fluorescent Biosensor Dynamics and Hormone Secretory Profiles
Published on: November 3, 2023
Artificial beta-cell: clinical experience toward an implantable closed-loop insulin delivery system
E Renard1, G Costalat, H Chevassus
1Endocrinology Department, Lapeyronie Hospital, Montpellier, France. e-renard@chu-montpellier.fr
Diabetes & Metabolism
|November 30, 2006
Summary
A fully implantable artificial beta cell is feasible for diabetic patients, but glucose control needs improvement. Enhancements in sensor longevity and response time are crucial for this advanced diabetes management system.
Area of Science:
- Biomedical Engineering
- Endocrinology
- Medical Devices
Background:
- Restoring normal blood glucose control is key for developing an artificial beta cell.
- Implantable systems integrating insulin delivery, glucose sensing, and control are under investigation.
Purpose of the Study:
- To assess the feasibility of a fully implantable artificial beta cell system.
- To evaluate glucose control using combined peritoneal insulin delivery and intravenous glucose sensing.
Main Methods:
- The Long-Term Sensor System project involved 10 Type 1 diabetic patients.
- Combined implantation of a peritoneal insulin pump and an intravenous glucose sensor was assessed.
- Closed-loop trials were conducted to evaluate automated glucose control.
Main Results:
- Implanted intravenous sensors were well-tolerated with no significant complications.
- Intravenous sensors showed good correlation with meter values (r=0.83-0.93) for an average of 9 months.
- Automated glucose control achieved was comparable to existing subcutaneous systems, but hampered by sensor delay.
Conclusions:
- The concept of a fully implantable artificial beta cell is feasible.
- Current performance in glucose control requires sensor improvements for longevity and reduced delay.
- Further development is needed to optimize artificial beta cell systems for diabetes management.
Related Concept Videos
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...